

# Global Refractory Multiple Myeloma Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GA8C18381D94EN.html>

Date: July 2024

Pages: 100

Price: US\$ 3,480.00 (Single User License)

ID: GA8C18381D94EN

## Abstracts

According to our (Global Info Research) latest study, the global Refractory Multiple Myeloma market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.

The Global Info Research report includes an overview of the development of the Refractory Multiple Myeloma industry chain, the market status of Hospital (Proteasome Inhibitor, Immunomodulators), Specialty Clinic (Proteasome Inhibitor, Immunomodulators), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Refractory Multiple Myeloma.

Regionally, the report analyzes the Refractory Multiple Myeloma markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Refractory Multiple Myeloma market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Refractory Multiple Myeloma market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Refractory Multiple Myeloma industry.

The report involves analyzing the market at a macro level:

**Market Sizing and Segmentation:** Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Proteosome Inhibitor, Immunomodulators).

**Industry Analysis:** Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Refractory Multiple Myeloma market.

**Regional Analysis:** The report involves examining the Refractory Multiple Myeloma market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

**Market Projections:** Report covers the gathered data and analysis to make future projections and forecasts for the Refractory Multiple Myeloma market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Refractory Multiple Myeloma:

**Company Analysis:** Report covers individual Refractory Multiple Myeloma players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

**Consumer Analysis:** Report covers data on consumer behaviour, preferences, and attitudes towards Refractory Multiple Myeloma This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Specialty Clinic).

**Technology Analysis:** Report covers specific technologies relevant to Refractory Multiple Myeloma. It assesses the current state, advancements, and potential future developments in Refractory Multiple Myeloma areas.

**Competitive Landscape:** By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Refractory Multiple Myeloma market. This analysis helps understand market share, competitive

advantages, and potential areas for differentiation among industry players.

**Market Validation:** The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

### Market Segmentation

Refractory Multiple Myeloma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

#### Market segment by Type

Proteasome Inhibitor

Immunomodulators

Anti-CD38 Monoclonal Antibody

Others

#### Market segment by Application

Hospital

Specialty Clinic

Others

#### Market segment by players, this report covers

Bristol Myers Squibb

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Janssen Global Services, LLC

Gilead Sciences, Inc.

Fresenius Kabi

GSK plc.

Novartis AG

Takeda Pharmaceutical Company Limited

Genentech, Inc.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Refractory Multiple Myeloma product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Refractory Multiple Myeloma, with revenue, gross margin and global market share of Refractory Multiple Myeloma from 2018 to 2023.

Chapter 3, the Refractory Multiple Myeloma competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Refractory Multiple Myeloma market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Refractory Multiple Myeloma.

Chapter 13, to describe Refractory Multiple Myeloma research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Refractory Multiple Myeloma

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Refractory Multiple Myeloma by Type

1.3.1 Overview: Global Refractory Multiple Myeloma Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Refractory Multiple Myeloma Consumption Value Market Share by Type in 2022

1.3.3 Proteasome Inhibitor

1.3.4 Immunomodulators

1.3.5 Anti-CD38 Monoclonal Antibody

1.3.6 Others

1.4 Global Refractory Multiple Myeloma Market by Application

1.4.1 Overview: Global Refractory Multiple Myeloma Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 Hospital

1.4.3 Specialty Clinic

1.4.4 Others

1.5 Global Refractory Multiple Myeloma Market Size & Forecast

1.6 Global Refractory Multiple Myeloma Market Size and Forecast by Region

1.6.1 Global Refractory Multiple Myeloma Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Refractory Multiple Myeloma Market Size by Region, (2018-2029)

1.6.3 North America Refractory Multiple Myeloma Market Size and Prospect (2018-2029)

1.6.4 Europe Refractory Multiple Myeloma Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Refractory Multiple Myeloma Market Size and Prospect (2018-2029)

1.6.6 South America Refractory Multiple Myeloma Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Refractory Multiple Myeloma Market Size and Prospect (2018-2029)

### 2 COMPANY PROFILES

2.1 Bristol Myers Squibb

2.1.1 Bristol Myers Squibb Details

- 2.1.2 Bristol Myers Squibb Major Business
- 2.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Product and Solutions
- 2.1.4 Bristol Myers Squibb Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 Bristol Myers Squibb Recent Developments and Future Plans
- 2.2 Teva Pharmaceutical Industries Ltd.
  - 2.2.1 Teva Pharmaceutical Industries Ltd. Details
  - 2.2.2 Teva Pharmaceutical Industries Ltd. Major Business
  - 2.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product and Solutions
  - 2.2.4 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  - 2.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
- 2.3 Pfizer Inc.
  - 2.3.1 Pfizer Inc. Details
  - 2.3.2 Pfizer Inc. Major Business
  - 2.3.3 Pfizer Inc. Refractory Multiple Myeloma Product and Solutions
  - 2.3.4 Pfizer Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  - 2.3.5 Pfizer Inc. Recent Developments and Future Plans
- 2.4 Janssen Global Services, LLC
  - 2.4.1 Janssen Global Services, LLC Details
  - 2.4.2 Janssen Global Services, LLC Major Business
  - 2.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Product and Solutions
  - 2.4.4 Janssen Global Services, LLC Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  - 2.4.5 Janssen Global Services, LLC Recent Developments and Future Plans
- 2.5 Gilead Sciences, Inc.
  - 2.5.1 Gilead Sciences, Inc. Details
  - 2.5.2 Gilead Sciences, Inc. Major Business
  - 2.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Product and Solutions
  - 2.5.4 Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
  - 2.5.5 Gilead Sciences, Inc. Recent Developments and Future Plans
- 2.6 Fresenius Kabi
  - 2.6.1 Fresenius Kabi Details
  - 2.6.2 Fresenius Kabi Major Business
  - 2.6.3 Fresenius Kabi Refractory Multiple Myeloma Product and Solutions

2.6.4 Fresenius Kabi Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Fresenius Kabi Recent Developments and Future Plans

2.7 GSK plc.

2.7.1 GSK plc. Details

2.7.2 GSK plc. Major Business

2.7.3 GSK plc. Refractory Multiple Myeloma Product and Solutions

2.7.4 GSK plc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

2.7.5 GSK plc. Recent Developments and Future Plans

2.8 Novartis AG

2.8.1 Novartis AG Details

2.8.2 Novartis AG Major Business

2.8.3 Novartis AG Refractory Multiple Myeloma Product and Solutions

2.8.4 Novartis AG Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

2.8.5 Novartis AG Recent Developments and Future Plans

2.9 Takeda Pharmaceutical Company Limited

2.9.1 Takeda Pharmaceutical Company Limited Details

2.9.2 Takeda Pharmaceutical Company Limited Major Business

2.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product and Solutions

2.9.4 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

2.9.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans

2.10 Genentech, Inc.

2.10.1 Genentech, Inc. Details

2.10.2 Genentech, Inc. Major Business

2.10.3 Genentech, Inc. Refractory Multiple Myeloma Product and Solutions

2.10.4 Genentech, Inc. Refractory Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)

2.10.5 Genentech, Inc. Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Refractory Multiple Myeloma Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Refractory Multiple Myeloma by Company Revenue



- 3.2.2 Top 3 Refractory Multiple Myeloma Players Market Share in 2022
- 3.2.3 Top 6 Refractory Multiple Myeloma Players Market Share in 2022
- 3.3 Refractory Multiple Myeloma Market: Overall Company Footprint Analysis
  - 3.3.1 Refractory Multiple Myeloma Market: Region Footprint
  - 3.3.2 Refractory Multiple Myeloma Market: Company Product Type Footprint
  - 3.3.3 Refractory Multiple Myeloma Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

- 4.1 Global Refractory Multiple Myeloma Consumption Value and Market Share by Type (2018-2023)
- 4.2 Global Refractory Multiple Myeloma Market Forecast by Type (2024-2029)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

- 5.1 Global Refractory Multiple Myeloma Consumption Value Market Share by Application (2018-2023)
- 5.2 Global Refractory Multiple Myeloma Market Forecast by Application (2024-2029)

## **6 NORTH AMERICA**

- 6.1 North America Refractory Multiple Myeloma Consumption Value by Type (2018-2029)
- 6.2 North America Refractory Multiple Myeloma Consumption Value by Application (2018-2029)
- 6.3 North America Refractory Multiple Myeloma Market Size by Country
  - 6.3.1 North America Refractory Multiple Myeloma Consumption Value by Country (2018-2029)
  - 6.3.2 United States Refractory Multiple Myeloma Market Size and Forecast (2018-2029)
  - 6.3.3 Canada Refractory Multiple Myeloma Market Size and Forecast (2018-2029)
  - 6.3.4 Mexico Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

## **7 EUROPE**

- 7.1 Europe Refractory Multiple Myeloma Consumption Value by Type (2018-2029)
- 7.2 Europe Refractory Multiple Myeloma Consumption Value by Application

(2018-2029)

### 7.3 Europe Refractory Multiple Myeloma Market Size by Country

7.3.1 Europe Refractory Multiple Myeloma Consumption Value by Country

(2018-2029)

7.3.2 Germany Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

7.3.3 France Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Refractory Multiple Myeloma Market Size and Forecast

(2018-2029)

7.3.5 Russia Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

7.3.6 Italy Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Refractory Multiple Myeloma Consumption Value by Type (2018-2029)

8.2 Asia-Pacific Refractory Multiple Myeloma Consumption Value by Application

(2018-2029)

8.3 Asia-Pacific Refractory Multiple Myeloma Market Size by Region

8.3.1 Asia-Pacific Refractory Multiple Myeloma Consumption Value by Region

(2018-2029)

8.3.2 China Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

8.3.3 Japan Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

8.3.4 South Korea Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

8.3.5 India Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Refractory Multiple Myeloma Market Size and Forecast

(2018-2029)

8.3.7 Australia Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

## **9 SOUTH AMERICA**

9.1 South America Refractory Multiple Myeloma Consumption Value by Type

(2018-2029)

9.2 South America Refractory Multiple Myeloma Consumption Value by Application

(2018-2029)

9.3 South America Refractory Multiple Myeloma Market Size by Country

9.3.1 South America Refractory Multiple Myeloma Consumption Value by Country

(2018-2029)

9.3.2 Brazil Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

9.3.3 Argentina Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Refractory Multiple Myeloma Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Refractory Multiple Myeloma Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Refractory Multiple Myeloma Market Size by Country

10.3.1 Middle East & Africa Refractory Multiple Myeloma Consumption Value by Country (2018-2029)

10.3.2 Turkey Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

10.3.4 UAE Refractory Multiple Myeloma Market Size and Forecast (2018-2029)

## **11 MARKET DYNAMICS**

11.1 Refractory Multiple Myeloma Market Drivers

11.2 Refractory Multiple Myeloma Market Restraints

11.3 Refractory Multiple Myeloma Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

11.5 Influence of COVID-19 and Russia-Ukraine War

11.5.1 Influence of COVID-19

11.5.2 Influence of Russia-Ukraine War

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Refractory Multiple Myeloma Industry Chain

12.2 Refractory Multiple Myeloma Upstream Analysis

12.3 Refractory Multiple Myeloma Midstream Analysis

12.4 Refractory Multiple Myeloma Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Refractory Multiple Myeloma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Refractory Multiple Myeloma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Refractory Multiple Myeloma Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Refractory Multiple Myeloma Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Bristol Myers Squibb Company Information, Head Office, and Major Competitors

Table 6. Bristol Myers Squibb Major Business

Table 7. Bristol Myers Squibb Refractory Multiple Myeloma Product and Solutions

Table 8. Bristol Myers Squibb Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Bristol Myers Squibb Recent Developments and Future Plans

Table 10. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors

Table 11. Teva Pharmaceutical Industries Ltd. Major Business

Table 12. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Product and Solutions

Table 13. Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans

Table 15. Pfizer Inc. Company Information, Head Office, and Major Competitors

Table 16. Pfizer Inc. Major Business

Table 17. Pfizer Inc. Refractory Multiple Myeloma Product and Solutions

Table 18. Pfizer Inc. Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Pfizer Inc. Recent Developments and Future Plans

Table 20. Janssen Global Services, LLC Company Information, Head Office, and Major Competitors

Table 21. Janssen Global Services, LLC Major Business

Table 22. Janssen Global Services, LLC Refractory Multiple Myeloma Product and Solutions

Table 23. Janssen Global Services, LLC Refractory Multiple Myeloma Revenue (USD

Million), Gross Margin and Market Share (2018-2023)

Table 24. Janssen Global Services, LLC Recent Developments and Future Plans

Table 25. Gilead Sciences, Inc. Company Information, Head Office, and Major Competitors

Table 26. Gilead Sciences, Inc. Major Business

Table 27. Gilead Sciences, Inc. Refractory Multiple Myeloma Product and Solutions

Table 28. Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Gilead Sciences, Inc. Recent Developments and Future Plans

Table 30. Fresenius Kabi Company Information, Head Office, and Major Competitors

Table 31. Fresenius Kabi Major Business

Table 32. Fresenius Kabi Refractory Multiple Myeloma Product and Solutions

Table 33. Fresenius Kabi Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Fresenius Kabi Recent Developments and Future Plans

Table 35. GSK plc. Company Information, Head Office, and Major Competitors

Table 36. GSK plc. Major Business

Table 37. GSK plc. Refractory Multiple Myeloma Product and Solutions

Table 38. GSK plc. Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 39. GSK plc. Recent Developments and Future Plans

Table 40. Novartis AG Company Information, Head Office, and Major Competitors

Table 41. Novartis AG Major Business

Table 42. Novartis AG Refractory Multiple Myeloma Product and Solutions

Table 43. Novartis AG Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 44. Novartis AG Recent Developments and Future Plans

Table 45. Takeda Pharmaceutical Company Limited Company Information, Head Office, and Major Competitors

Table 46. Takeda Pharmaceutical Company Limited Major Business

Table 47. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Product and Solutions

Table 48. Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 49. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans

Table 50. Genentech, Inc. Company Information, Head Office, and Major Competitors

Table 51. Genentech, Inc. Major Business

Table 52. Genentech, Inc. Refractory Multiple Myeloma Product and Solutions

Table 53. Genentech, Inc. Refractory Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 54. Genentech, Inc. Recent Developments and Future Plans

Table 55. Global Refractory Multiple Myeloma Revenue (USD Million) by Players (2018-2023)

Table 56. Global Refractory Multiple Myeloma Revenue Share by Players (2018-2023)

Table 57. Breakdown of Refractory Multiple Myeloma by Company Type (Tier 1, Tier 2, and Tier 3)

Table 58. Market Position of Players in Refractory Multiple Myeloma, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022

Table 59. Head Office of Key Refractory Multiple Myeloma Players

Table 60. Refractory Multiple Myeloma Market: Company Product Type Footprint

Table 61. Refractory Multiple Myeloma Market: Company Product Application Footprint

Table 62. Refractory Multiple Myeloma New Market Entrants and Barriers to Market Entry

Table 63. Refractory Multiple Myeloma Mergers, Acquisition, Agreements, and Collaborations

Table 64. Global Refractory Multiple Myeloma Consumption Value (USD Million) by Type (2018-2023)

Table 65. Global Refractory Multiple Myeloma Consumption Value Share by Type (2018-2023)

Table 66. Global Refractory Multiple Myeloma Consumption Value Forecast by Type (2024-2029)

Table 67. Global Refractory Multiple Myeloma Consumption Value by Application (2018-2023)

Table 68. Global Refractory Multiple Myeloma Consumption Value Forecast by Application (2024-2029)

Table 69. North America Refractory Multiple Myeloma Consumption Value by Type (2018-2023) & (USD Million)

Table 70. North America Refractory Multiple Myeloma Consumption Value by Type (2024-2029) & (USD Million)

Table 71. North America Refractory Multiple Myeloma Consumption Value by Application (2018-2023) & (USD Million)

Table 72. North America Refractory Multiple Myeloma Consumption Value by Application (2024-2029) & (USD Million)

Table 73. North America Refractory Multiple Myeloma Consumption Value by Country (2018-2023) & (USD Million)

Table 74. North America Refractory Multiple Myeloma Consumption Value by Country (2024-2029) & (USD Million)



Table 75. Europe Refractory Multiple Myeloma Consumption Value by Type (2018-2023) & (USD Million)

Table 76. Europe Refractory Multiple Myeloma Consumption Value by Type (2024-2029) & (USD Million)

Table 77. Europe Refractory Multiple Myeloma Consumption Value by Application (2018-2023) & (USD Million)

Table 78. Europe Refractory Multiple Myeloma Consumption Value by Application (2024-2029) & (USD Million)

Table 79. Europe Refractory Multiple Myeloma Consumption Value by Country (2018-2023) & (USD Million)

Table 80. Europe Refractory Multiple Myeloma Consumption Value by Country (2024-2029) & (USD Million)

Table 81. Asia-Pacific Refractory Multiple Myeloma Consumption Value by Type (2018-2023) & (USD Million)

Table 82. Asia-Pacific Refractory Multiple Myeloma Consumption Value by Type (2024-2029) & (USD Million)

Table 83. Asia-Pacific Refractory Multiple Myeloma Consumption Value by Application (2018-2023) & (USD Million)

Table 84. Asia-Pacific Refractory Multiple Myeloma Consumption Value by Application (2024-2029) & (USD Million)

Table 85. Asia-Pacific Refractory Multiple Myeloma Consumption Value by Region (2018-2023) & (USD Million)

Table 86. Asia-Pacific Refractory Multiple Myeloma Consumption Value by Region (2024-2029) & (USD Million)

Table 87. South America Refractory Multiple Myeloma Consumption Value by Type (2018-2023) & (USD Million)

Table 88. South America Refractory Multiple Myeloma Consumption Value by Type (2024-2029) & (USD Million)

Table 89. South America Refractory Multiple Myeloma Consumption Value by Application (2018-2023) & (USD Million)

Table 90. South America Refractory Multiple Myeloma Consumption Value by Application (2024-2029) & (USD Million)

Table 91. South America Refractory Multiple Myeloma Consumption Value by Country (2018-2023) & (USD Million)

Table 92. South America Refractory Multiple Myeloma Consumption Value by Country (2024-2029) & (USD Million)

Table 93. Middle East & Africa Refractory Multiple Myeloma Consumption Value by Type (2018-2023) & (USD Million)

Table 94. Middle East & Africa Refractory Multiple Myeloma Consumption Value by



Type (2024-2029) & (USD Million)

Table 95. Middle East & Africa Refractory Multiple Myeloma Consumption Value by Application (2018-2023) & (USD Million)

Table 96. Middle East & Africa Refractory Multiple Myeloma Consumption Value by Application (2024-2029) & (USD Million)

Table 97. Middle East & Africa Refractory Multiple Myeloma Consumption Value by Country (2018-2023) & (USD Million)

Table 98. Middle East & Africa Refractory Multiple Myeloma Consumption Value by Country (2024-2029) & (USD Million)

Table 99. Refractory Multiple Myeloma Raw Material

Table 100. Key Suppliers of Refractory Multiple Myeloma Raw Materials

## List Of Figures

### LIST OF FIGURES

s

Figure 1. Refractory Multiple Myeloma Picture

Figure 2. Global Refractory Multiple Myeloma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Refractory Multiple Myeloma Consumption Value Market Share by Type in 2022

Figure 4. Proteasome Inhibitor

Figure 5. Immunomodulators

Figure 6. Anti-CD38 Monoclonal Antibody

Figure 7. Others

Figure 8. Global Refractory Multiple Myeloma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 9. Refractory Multiple Myeloma Consumption Value Market Share by Application in 2022

Figure 10. Hospital Picture

Figure 11. Specialty Clinic Picture

Figure 12. Others Picture

Figure 13. Global Refractory Multiple Myeloma Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 14. Global Refractory Multiple Myeloma Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 15. Global Market Refractory Multiple Myeloma Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 16. Global Refractory Multiple Myeloma Consumption Value Market Share by Region (2018-2029)

Figure 17. Global Refractory Multiple Myeloma Consumption Value Market Share by Region in 2022

Figure 18. North America Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 20. Asia-Pacific Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 21. South America Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 22. Middle East and Africa Refractory Multiple Myeloma Consumption Value

(2018-2029) & (USD Million)

Figure 23. Global Refractory Multiple Myeloma Revenue Share by Players in 2022

Figure 24. Refractory Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 25. Global Top 3 Players Refractory Multiple Myeloma Market Share in 2022

Figure 26. Global Top 6 Players Refractory Multiple Myeloma Market Share in 2022

Figure 27. Global Refractory Multiple Myeloma Consumption Value Share by Type (2018-2023)

Figure 28. Global Refractory Multiple Myeloma Market Share Forecast by Type (2024-2029)

Figure 29. Global Refractory Multiple Myeloma Consumption Value Share by Application (2018-2023)

Figure 30. Global Refractory Multiple Myeloma Market Share Forecast by Application (2024-2029)

Figure 31. North America Refractory Multiple Myeloma Consumption Value Market Share by Type (2018-2029)

Figure 32. North America Refractory Multiple Myeloma Consumption Value Market Share by Application (2018-2029)

Figure 33. North America Refractory Multiple Myeloma Consumption Value Market Share by Country (2018-2029)

Figure 34. United States Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 35. Canada Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 36. Mexico Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 37. Europe Refractory Multiple Myeloma Consumption Value Market Share by Type (2018-2029)

Figure 38. Europe Refractory Multiple Myeloma Consumption Value Market Share by Application (2018-2029)

Figure 39. Europe Refractory Multiple Myeloma Consumption Value Market Share by Country (2018-2029)

Figure 40. Germany Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 41. France Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 42. United Kingdom Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 43. Russia Refractory Multiple Myeloma Consumption Value (2018-2029) &

(USD Million)

Figure 44. Italy Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 45. Asia-Pacific Refractory Multiple Myeloma Consumption Value Market Share by Type (2018-2029)

Figure 46. Asia-Pacific Refractory Multiple Myeloma Consumption Value Market Share by Application (2018-2029)

Figure 47. Asia-Pacific Refractory Multiple Myeloma Consumption Value Market Share by Region (2018-2029)

Figure 48. China Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 49. Japan Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 50. South Korea Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 51. India Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 52. Southeast Asia Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 53. Australia Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 54. South America Refractory Multiple Myeloma Consumption Value Market Share by Type (2018-2029)

Figure 55. South America Refractory Multiple Myeloma Consumption Value Market Share by Application (2018-2029)

Figure 56. South America Refractory Multiple Myeloma Consumption Value Market Share by Country (2018-2029)

Figure 57. Brazil Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 58. Argentina Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 59. Middle East and Africa Refractory Multiple Myeloma Consumption Value Market Share by Type (2018-2029)

Figure 60. Middle East and Africa Refractory Multiple Myeloma Consumption Value Market Share by Application (2018-2029)

Figure 61. Middle East and Africa Refractory Multiple Myeloma Consumption Value Market Share by Country (2018-2029)

Figure 62. Turkey Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 63. Saudi Arabia Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 64. UAE Refractory Multiple Myeloma Consumption Value (2018-2029) & (USD Million)

Figure 65. Refractory Multiple Myeloma Market Drivers

Figure 66. Refractory Multiple Myeloma Market Restraints

Figure 67. Refractory Multiple Myeloma Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Manufacturing Cost Structure Analysis of Refractory Multiple Myeloma in 2022

Figure 70. Manufacturing Process Analysis of Refractory Multiple Myeloma

Figure 71. Refractory Multiple Myeloma Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source

## I would like to order

Product name: Global Refractory Multiple Myeloma Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GA8C18381D94EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA8C18381D94EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

